| P/E (FY) | — | Sales (TTM) | $4.9M |
| Earnings (TTM) | -$175.9M | ROE | −149.83% |
| Net Margin | −2607.29% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 5.18% |
| Market Cap | $4.00B | Trading Days | 2817 |
| 52W High | 26.18 |
| 52W Low | 8.51 |
| % Off High | −48.44% |
| YTD | −29.58% | 1Y | 38.75% |
| 3Y | 327.22% | 5Y | 16.78% |
| 10Y | −80.73% | Since incept. (ann.) | −9.86% |
| Ann. Volatility (1Y) | 76.33% | Ann. Volatility (3Y) | 322.43% |
| Sharpe (1Y) | 0.80 | Sharpe (3Y) | 0.62 |
| Max Drawdown (1Y) | −44.99% | Max Drawdown (3Y) | −86.60% |
| Beta (3Y, vs SPY) | 2.76 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | $3.82B | — |
| SCNI | Scinai Immunotherapeutics Ltd. | $3.66B | — |
| ADPT | Adaptive Biotechnologies Corp | $3.60B | — |
| RLAY | Relay Therapeutics, Inc. | $3.50B | — |
| CRSP | CRISPR Therapeutics AG | $4.59B | — |
| TWST | Twist Bioscience Corp | $5.51B | — |
| BEAM | Beam Therapeutics Inc. | $2.70B | — |
| SRRK | Scholar Rock Holding Corp | $5.92B | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| KOD | Kodiak Sciences Inc. | $2.52B | — |
| CGON | CG Oncology, Inc. |
| $6.41B |
| — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
